Načítá se...
Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma
BACKGROUND: Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to standard chemotherapy was conducted, which showed clinical benefit of trabectedi...
Uloženo v:
Vydáno v: | BMC Cancer |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
BioMed Central
2016
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4946242/ https://ncbi.nlm.nih.gov/pubmed/27418251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2511-y |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|